综述

特异AT序列结合蛋白2(SATB2)的研究进展

展开
  • 1. 复旦大学上海医学院分子医学教育部重点实验室, 上海 200032 2. 复旦大学生物医学研究院,复旦大学出生缺陷研究中心, 上海 200032

收稿日期: 2010-11-12

  修回日期: 2010-12-07

  网络出版日期: 2011-09-25

基金资助

上海科委基础研究重点项目(编号:10JC1402602)资助

Study progress of special AT-rich sequence binding protein 2

Expand
  • 1. Key Laboratory of Molecular Medicine, Ministry of Education, Department of Biochemistry and Molecular Biology, Shanghai Medical College, Fudan University, Shanghai 200032, China 2. Institutes of Biomedical Science, Resaerch Center for Birth Defects, Fudan University, Shanghai 200032, China

Received date: 2010-11-12

  Revised date: 2010-12-07

  Online published: 2011-09-25

摘要

特异AT序列结合蛋白2(SATB2)是与核基质结合区结合的转录因子, 在转录调控和染色质重组等过程中发挥重要作用。SATB2是成骨细胞分化和骨基质形成过程中的关键调控分子, 其突变可导致先天性颌面部畸形的发生; SATB2是中枢神经系统发育过程中的核心分子, 在胼胝体、脑桥等正常发育中起重要作用; SATB2也参与肿瘤的发生, 在乳腺癌等恶性肿瘤中的表达升高。文章就上述各领域中SATB2的研究进展进行了综述。

本文引用格式

钱琰琰,王慧君,马端 . 特异AT序列结合蛋白2(SATB2)的研究进展[J]. 遗传, 2011 , 33(9) : 947 -952 . DOI: 10.3724/SP.J.1005.2011.00947

Abstract

SATB2 is a transcription factor, which plays an important role in transcriptional regulation and chromatin recombinant by combining with matrix attachment regions. SATB2 is a key regulatory molecule in the progress of osteoblast differentiation and bone matrix formation. Mutations in this gene are associated with congenital craniofacial malformation. In addition, SATB2 is involved in the development of central nervous system, especially the corpus callosum and the pons. At the same time, SATB2 may participate in the process of tumor formation. In malignant tumors, such as breast cancer, the expression level of SATB2 is higher than normal. The literatures of SATB2 were reviewed in this article.

参考文献

[1] Rosenfeld JA, Ballif BC, Lucas A, Spence EJ, Powell C, Aylsworth AS, Torchia BA, Shaffer LG. Small deletions of SATB2 cause some of the clinical features of the 2q33.1 microdeletion syndrome. PLoS One, 2009, 4(8): e6568.
[2] Brugmann SA, Powder KE, Young NM, Goodnough LH, Hahn SM, James AW, Helms JA, Lovett M. Comparative gene expression analysis of avian embryonic facial structures reveals new candidates for human craniofacial disorders. Hum Mol Genet, 2010, 19(5): 920-930.
[3] Depew MJ, Compagnucci C. Tweaking the hinge and caps: testing a model of the organization of jaw. J Exp Zool B Mol Dev Evol, 2008, 310B(4): 315-335.
[4] Ahn HJ, Park Y, Kim S, Park HC, Seo SK, Yeo SY, Geum D. The expression profile and function of Satb2 in zebrafish embryonic development. Mol Cells, 2010, 30(4): 377-382
[5] Dobreva G, Dambacher J, Grosschedl R. SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin μ gene expression. Genes Dev, 2003, 17(24): 3048-3061.
[6] Hassan MQ, Gordon JAR, Beloti MM, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian JB. A network connecting Runx2, SATB2, and the miR-23a~27a~24-2 cluster regulates the osteoblast differentiation program. Proc Natl Acad Sci USA, 2010, 107(46): 19879-19884.
[7] Dobreva G, Chahrour M, Dautzenberg M, Chirivella L, Kanzler B, Fariñas I, Karsenty G, Grosschedl R. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell, 2006, 125(5): 971-986.
[8] Mao XY, Tang SJ. Effects of phenytoin on Satb2 and Hoxa2 gene expressions in mouse embryonic craniofacial tissue. Biochem Cell Biol, 2010, 88(4): 731-735.
[9] Ellies DL, Krumlauf R. Bone formation: The nuclear matrix reloaded. Cell, 2006, 125(5): 840-842.
[10] Yu VWC, Akhouayri O, St-Arnaud R. FIAT is co-expressed with its dimerization target ATF4 in early osteoblasts, but not in osteocytes. Gene Expr Patterns, 2009, 9(5): 335-340.
[11] Britanova O, Depew MJ, Schwark M, Thomas BL, Miletich I, Sharpe P, Tarabykin V. Satb2 haploinsufficiency phenocopies 2q32-q33 deletions, whereas loss suggests a fundamental role in the coordination of jaw development. Am J Hum Genet, 2006, 79(4): 668-678.
[12] Fitzpatrick DR, Carr IM, McLaren L, Leek JP, Wightman P, Williamson K, Gautier P, McGill N, Hayward C, Firth H, Markham AF, Fantes JA, Bonthron DT. Identification of SATB2 as the cleft palate gene on 2q32-q33. Hum Mol Genet, 2003, 12(19): 2491-2501.
[13] Vieira AR, Avila JR, Daack-Hirsch S, Dragan E, Félix TM, Rahimov F, Harrington J, Schultz RR, Watanabe Y, Johnson M, Fang J, O'Brien SE, Orioli IM, Castilla EE, FitzPatrick DR, Jiang RL, Marazita ML, Murray JC. Medical sequencing of candidate genes for nonsyndromic cleft lip and palate. PLoS Genet, 2005, 1(6): e64.
[14] van Buggenhout G, van Ravenswaaij-Arts C, Mc Maas N, Thoelen R, Vogels A, Smeets D, Salden I, Matthijs G, Fryns JP, Vermeesch JR. The del(2)(q32.2q33) deletion syndrome de?ned by clinical and molecular characterization of four pa-tients. Eur J Med Genet, 2005, 48(3): 276-289.
[15] Carter TC, Molloy AM, Pangilinan F, Troendle JF, Kirke PN, Conley MR, Orr DJA, Earley M, McKiernan E, Lynn EC, Doyle A, Scott JM, Brody LC, Mills JL. Testing reported associations of genetic risk factors for oral clefts in a large Irish study population. Birth Defects Res A Clin Mol Teratol, 2010, 88(2): 84-93.
[16] Urquhart J, Black GCM, Clayton-Smith J. 4.5 Mb microdeletion in chromosome band 2q33.1 associated with learning disability and cleft palate. Eur J Med Genet, 2009, 52(6): 454-457.
[17] Beaty TH, Hetmanski JB, Fallin MD, Park JW, Sull JW, McIntosh I, Liang KY, VanderKolk CA, Redett RJ, Boyadjiev SA, Jabs EW, Chong SS, Cheah FSH, Wu-Chou YH, Chen PK, Chiu YF, Yeow
文章导航

/